Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 20 October 2009
Vol. 2, Issue 93, p. pe65
[DOI: 10.1126/scisignal.293pe64]

PERSPECTIVES

Emerging Miniaturized Proteomic Technologies to Study Cell Signaling in Clinical Samples

Taranjit S. Gujral* and Gavin MacBeath*

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.

Abstract: Recording the state and dynamics of intracellular signaling networks in clinical specimens can help identify and validate biomarkers, but may also prove useful in developing and monitoring targeted therapies. Studying cell signaling on a system-wide level in solid tissue, however, is often not feasible using mass spectrometry, because this technique generally requires relatively large sample quantities. A number of promising miniaturized proteomic technologies have emerged, which circumvent these limitations and offer the ability to monitor protein abundances and posttranslational modification states in a multiplexed and quantitative fashion. These technologies have the potential to accelerate molecular diagnostics and therapeutics, and may ultimately facilitate the broad adoption of personalized approaches to patient management and treatment.

* Corresponding author. E-mail, gujral{at}chemistry.harvard.edu; macbeath{at}chemistry.harvard.edu

Citation: T. S. Gujral, G. MacBeath, Emerging Miniaturized Proteomic Technologies to Study Cell Signaling in Clinical Samples. Sci. Signal. 2, pe65 (2009).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882